Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602367 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01602367: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT01602367 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01602367, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-823778 is safe and effective in the treatment of hypertension in overweight and obese patients.
Interventions
- DRUG BMS-823778
- DRUG Placebo matching with BMS-823778
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Why NCT01602367 stopped before completion
NCT01602367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which BMS-823778 is the first listed.
NCT01602367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01602367 about?
NCT01602367 is a clinical study titled "Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients". The purpose of this study is to determine whether BMS-823778 is safe and effective in the treatment of hypertension in overweight and obese patients.
What is the current status of trial NCT01602367?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2012-07. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01602367?
The interventions under investigation include: BMS-823778 (DRUG), Placebo matching with BMS-823778 (DRUG).
Who is sponsoring clinical trial NCT01602367?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01602367's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia